Biocon Limited (NSE:BIOCON)
India
· Delayed Price · Currency is INR 359.10
-1.15 (-0.32%)
Aug 14, 2025, 3:30 PM IST
Biocon Revenue
Biocon had revenue of 39.42B INR in the quarter ending June 30, 2025, with 14.83% growth. This brings the company's revenue in the last twelve months to 157.71B, up 6.80% year-over-year. In the fiscal year ending March 31, 2025, Biocon had annual revenue of 152.62B with 3.43% growth.
Revenue (ttm)
157.71B
Revenue Growth
+6.80%
P/S Ratio
3.04
Revenue / Employee
9.67M
Employees
16,315
Market Cap
479.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 152.62B | 5.06B | 3.43% |
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Divi's Laboratories | 96.52B |
| Cipla | 274.80B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 129.10B |
| Zydus Lifesciences | 232.42B |
| Fortis Healthcare | 80.94B |
| Aurobindo Pharma | 320.25B |
Biocon News
- 5 days ago - Profit margins, US medicine supplies may get hit: Biocon - The Times of India
- 7 days ago - Biocon Q1 net profit falls 95% to Rs 31 crore - The Times of India
- 22 days ago - Biocon Biologics launches Nepexto, a biosimilar to Enbrel, in Australia - Business Upturn
- 4 weeks ago - Top stocks in focus on July 16: Biocon, Dixon Technologies, IndiGo, ICICI Lombard, HDFC Life and more - Business Upturn
- 5 weeks ago - Biocon to announce Q1 FY26 results on August 7 - Business Upturn
- 5 weeks ago - It’s wrong to blame Covid jabs for cardiac arrests: Biocon chief Kiran Mazumdar-Shaw - The Times of India
- 5 weeks ago - 'Caution Not Anti-Science': Siddaramaiah On Covid Vaccine-Sudden Death Claim - NDTV
- 6 weeks ago - Biocon Chief Counters Siddaramaiah's Covid Vaccine-Heart Attack Link Claim - NDTV